Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncodesign Biotechnology, a company engaged in discovery of anti-cancer therapies, has taken over all commercialization rights for distributing collection of human colorectal cancer models directly developed from patient's tumors.
Subscribe to our email newsletter
With this acquisition, Oncodesign’s clients are now eligible to access the entire collection to assess therapeutic compounds in house or to carry out preclinical studies with Oncodesign.
The new collection has integrated Oncodesign’s Chi-Mice platform, designed to provide preclinical models from human samples.
The Chi-Mice platform includes both reconstituted human immune system models on NSG/NOG mice and models xenografted with patient-derived tumors.
Oncodesign president and CEO Philippe Genne said this collection is the result of a five year research program, and is comprehensive worldwide in terms of the range of genetic heterogeneity and characterization.